Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By

Showing results 21 - 28 of 28

Selected Filters:
7 July 2022

DISCOVER study for HIV pre-exposure prophylaxis (PrEP): F/TAF has a more rapid onset and longer sustained duration of HIV protection compared with F/TDF

In the DISCOVER study, F/TAF oral PrEP (Descovy) was statistically noninferior to F/TDF oral PrEP (Truvada). However, there were numerically 53% fewer HIV infections in the F/TAF arm vs. F/TDF . This study explores HIV risk, STIs, adherence, and pharmacokinetic data to evaluate this imbalance.

Research

External Link
7 July 2022

DISCOVER Trial Factsheet

This factsheet provides details on the DISCOVER trial to assess whether F/TAF (trade name Descovy) is as safe and effective as an oral daily HIV pre-exposure prophylaxis (PrEP) product.

Community/Advocacy, Research

External Link
7 July 2022

Descovy for PrEP

The U.S. Food and Drug Administration has reported that they have approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) who at at risk of acquiring HIV.

Normative Guidance/Policies

External Link
7 July 2022

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic

This article announces the U.S. Food and Drug Administration's approval of Descovy in at-risk adults and adolescents for HIV pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection from sex, excluding those who have receptive vaginal sex.

Normative Guidance/Policies

External Link
7 July 2022

Descovy for PrEP – FDA Supplemental Approval

This letter from the US Food and Drug Administration outlines supplemental approval granted to Descovy, an oral PrEP medication.

Normative Guidance/Policies

External Link
2 April 2020

Dapivirine Ring Compendium of End-User Insights

A summary of existing end-user research findings related to the ring and gaps remaining, all in a digestible compendium.

Research

Document
17 December 2018

PrEP for the Prevention of HIV Infection of HIV Infection in the United States – 2017 Update

Preexposure Prophylaxis for HIV Prevention in the United States – 2017 Update: A Clinical Practice Guideline provides comprehensive information for the use of daily oral antiretroviral preexposure prophylaxis (PrEP) to reduce the risk of acquiring HIV infection in adults.

Normative Guidance/Policies

Document
17 December 2018

National HIV/AIDS Strategy for the United States (2015 – 2020)

The nation’s comprehensive strategy for HIV/AIDS prevention and treatment.

Normative Guidance/Policies

Document